PurpleLab Accelerates Clinical Trial Lifecycle with Real-World-Data This video was created in collaboration with the Applied Clinical Trials. Approximately 80% of clinical trials will face delays at some point in the trial process. Jason Gagner talked with ACT about how PurpleLab uses real-world data to better inform trials and improve their success rates. Learn More About: Utilizing…

This study was run to determine if a racial disparity exists in biomarker testing for NSCLC (non-small cell lung cancer) patients. Jared Safran, PharmD, MS, Russell Robbins, MD, MBA, Maggie Mendes, Douglas Londono, PhD, Grace Kane, MS. Healthcare is evolving into precision medicine or what the FDA refers to as personalized medicine1. This targeted approach…

PurpleLab’s® Clinical Trial data provides detailed metrics on clinical trial activities performed by healthcare providers (HCPs) and healthcare organizations (HCOs). By integrating clinical trial data, overall profiles of HCPs and HCOs are enhanced, offering a clearer view of a provider’s clinical research experience. With this added visibility, users can efficiently segment and identify potential investigators and…

This study was run to evaluate whether provider specialty is a driver for biosimilar adoption, defined as adoption probability difference (APD). Diane Faraone, PharmD, Russell Robbins, MD, MBA, Grace Kane, MS, Douglas Londono, PhD.  The US biologics market has significantly expanded in recent years; projected to reach $62 billion in prescription drug spend by 2025. Biosimilar…

PurpleLab® goes further than raw claims data, by serving longitudinal patient data in combination with our no-code HealthNexus platform, to deliver on-demand insights, in minutes. HealthNexus, harmonizes the complex intersections created by the array of disparate healthcare vocabularies that annotate the factual account of a patient’s journey along with the reporting dimensions of critical need….

The Data-Driven Path to Biosimilar Success | Data Dive with PurpleLab This podcast was created in collaboration with the Pharmacy Podcast Network. In this episode, we are exploring a fascinating topic: how real-world data is reshaping the landscape of biosimilars. Dr. Russell Robbins, Chief Medical Information Officer and Dr. Diane Faraone, Senior Director in Pharmacy…

Data-Driven Diversity: PurpleLab’s Approach to Inclusive Clinical Trials This podcast was created in collaboration with the Pharmacy Podcast Network. In this episode, we delve into the critical topic of Diversity, Equity, and Inclusion (DEI) in clinical trials. Todd introduces PurpleLab and welcomes Dr. Russell Robbins, Chief Medical Information Management for Life Sciences. Together, they explore…

Glucagon-like peptide-1 (GLP-1) agonists are a class of medications frequently used to treat type 2 diabetes mellitus (T2DM) and obesity.[1] This class of medications assists in lowering blood sugar levels and promotes weight loss. In addition to treating diabetics, these medications are also used to treat obesity in diabetics as well as non-diabetics.   GLP-1 drugs…

Open claims and closed claims data serve as vital tools for comprehending patients’ progress and engagements throughout their healthcare voyage. However, which data type proves most advantageous and under what circumstances? Whether the need is to assess the cost-effectiveness of a recently introduced medication or streamline clinical trial recruitment, both open claims data and closed…